Drug Shortage Report for TEVA-IRBESARTAN HCTZ

Last updated on 2021-09-10 History
Report ID 101725
Drug Identification Number 02330512
Brand name TEVA-IRBESARTAN HCTZ
Common or Proper name IRBESARTAN/HCTZ 150/12.5MG TAB
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) HYDROCHLOROTHIAZIDE IRBESARTAN
Strength(s) 12.5MG 150MG
Dosage form(s) TABLET
Route of administration ORAL
Packaging size 100
ATC code C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-12-18
Estimated end date 2021-09-30
Actual end date 2021-09-09
Shortage status Resolved
Updated date 2021-09-10
Company comments Allocating 100% of Teva market share from July to October 2020.
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2019-12-19 English Compare
v2 2019-12-19 French Compare
v3 2020-01-09 English Compare
v4 2020-01-09 French Compare
v5 2020-01-30 English Compare
v6 2020-01-30 French Compare
v7 2020-03-05 English Compare
v8 2020-03-05 French Compare
v9 2020-04-09 English Compare
v10 2020-04-09 French Compare
v11 2020-04-23 English Compare
v12 2020-04-23 French Compare
v13 2020-05-01 English Compare
v14 2020-05-01 French Compare
v15 2020-05-08 English Compare
v16 2020-05-08 French Compare
v17 2020-05-14 English Compare
v18 2020-05-14 French Compare
v19 2020-06-18 English Compare
v20 2020-06-18 French Compare

Showing 1 to 20 of 34